Literature DB >> 7910953

A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis.

G Christofori1, P Naik, D Hanahan.   

Abstract

Transgenic mice expressing the simian virus-40 large T-antigen (Tag) under the control of the insulin gene regulatory region offer a useful model for tumorigenesis. All the islets of Langerhans express Tag, although there is at first no aberrant proliferation. Over half of the islets become hyperplastic, however, and neovascularization of a further subset (about 10%)3 leads eventually to formation of highly vascularized solid tumours in 1-2% of islets by about 14 weeks of age. Here we show that the initial proliferative switch is correlated with focal activation of insulin-like growth factor II (IGF-II). Transfection with an antisense oligonucleotide to the IGF-II messenger RNA interferes with tumour cell proliferation in vitro, and transgenic mice homozygous for a disruption of the IGF-II gene develop tumours with reduced malignancy and a higher incidence of apoptosis. Several signals, in this case including an oncoprotein and a growth/survival factor, thus appear to be needed to elicit hyperproliferation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910953     DOI: 10.1038/369414a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  94 in total

Review 1.  IGF and insulin action in the mammary gland: lessons from transgenic and knockout models.

Authors:  D L Hadsell; S G Bonnette
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

2.  Cancer epigenetics takes center stage.

Authors:  A P Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

3.  Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis.

Authors:  E M Tan
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

4.  Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.

Authors:  Danielle B Ulanet; Dale L Ludwig; C Ronald Kahn; Douglas Hanahan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

5.  Horizontal transfer of oncogenes by uptake of apoptotic bodies.

Authors:  A Bergsmedh; A Szeles; M Henriksson; A Bratt; M J Folkman; A L Spetz; L Holmgren
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

6.  Protein 4.1B in mouse islets of Langerhans and beta-cell tumorigenesis.

Authors:  Nobuo Terada; Nobuhiko Ohno; Hisashi Yamakawa; Takeshi Baba; Yasuhisa Fujii; Gerhard Christofori; Osamu Ohara; Shinichi Ohno
Journal:  Histochem Cell Biol       Date:  2003-09-09       Impact factor: 4.304

7.  Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy.

Authors:  P de Lonlay; J C Fournet; J Rahier; M S Gross-Morand; F Poggi-Travert; V Foussier; J P Bonnefont; M C Brusset; F Brunelle; J J Robert; C Nihoul-Fékété; J M Saudubray; C Junien
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

8.  Association of insulin receptor substrate 1 with simian virus 40 large T antigen.

Authors:  Z L Fei; C D'Ambrosio; S Li; E Surmacz; R Baserga
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

9.  A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma.

Authors:  Xiaoming Yao; Ji-Fan Hu; Mark Daniels; Hadas Shiran; Xiangjun Zhou; Huifan Yan; Hongqi Lu; Zhilan Zeng; Qingxue Wang; Tao Li; Andrew R Hoffman
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

10.  Loss of IGF2 imprinting is associated with abrogation of long-range intrachromosomal interactions in human cancer cells.

Authors:  Thanh H Vu; An H Nguyen; Andrew R Hoffman
Journal:  Hum Mol Genet       Date:  2009-12-16       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.